Ticagrelor is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year.
#Pegasus timi 54 full
While the preliminary analysis did not reveal any unexpected safety issues, the full evaluation of the data is ongoing.Ĭomplete study results would be submitted to a scientific meeting in 2015 and pending further analysis, AstraZeneca intends to file this data with regulatory health authorities. The study was designed to better understand the management of patients more than 12 months after their heart attack, who remain at high risk for major thrombotic events. Please DO NOT change anti-platelet regimens without discussion with the responsible consultant interventional cardiologist for that patient.
#Pegasus timi 54 trial
The PEGASUS-TIMI 54 trial investigated two different doses of ticagrelor on a background of low dose aspirin versus placebo plus low dose aspirin, in patients aged 50 and older with a history of heart attack and one additional CV risk factor1. Consider, after the 12 months of dual anti-platelet therapy, Ticagrelor 60mg bd for a further 3 years (following the PEGASUS-TIMI 54 RCT). The primary efficacy endpoint was a composite of cardiovascular or CV death, myocardial infarction or MI or stroke. The study, a large scale outcomes trial involving more than 21,000 patients, evaluated BRILINTA tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. LONDON (dpa-AFX) - British drugmaker AstraZeneca PLC (AZN, AZN.L) reported that the PEGASUS-TIMI 54 study achieved its primary efficacy endpoint.
0 kommentar(er)
